NAMA
DNA icon

Nikko Asset Management Americas’s Ginkgo Bioworks DNA Stock Holding History

Nikko Asset Management Americas’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54,193
Closed -$715K – 189
2024
Q2 		$715K Sell
54,193
-1,342,433
-96% -$40.1M 0.01% 168
2024
Q1 		$64.8M Sell
1,396,626
-59,347
-4% -$3.07M 0.64% 42
2023
Q4 		$97.8M Sell
1,455,973
-12,681
-0.9% -$776K 0.94% 28
2023
Q3 		$106M Buy
1,468,654
+198,965
+16% +$15.9M 1.27% 23
2023
Q2 		$94M Buy
1,269,689
+204,774
+19% +$12.1M 0.99% 26
2023
Q1 		$55.8M Buy
1,064,915
+127,057
+14% +$8.05M 0.64% 33
2022
Q4 		$63.4M Buy
937,858
+163,309
+21% +$15M 0.91% 29
2022
Q3 		$98.5M Buy
774,549
+228,095
+42% +$27.2M 1.26% 21
2022
Q2 		$52.7M Buy
546,454
+173,429
+46% +$21.2M 0.65% 37
2022
Q1 		$61.5M Buy
373,025
+90,350
+32% +$17.6M 0.45% 44
2021
Q4 		$96.8M Buy
282,675
+168,858
+148% +$80.2M 0.51% 40
2021
Q3 		$52.8M Buy
+113,817
New +$55.4M 0.23% 77

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nikko Asset Management Americas's DNA Position: Q3 2024 in Review

Nikko Asset Management Americas sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 54,193 shares — an estimated $715K sold.

Nikko Asset Management Americas first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $106M in Q3 2023. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Nikko Asset Management Americas reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Nikko Asset Management Americas sold 54,193 Ginkgo Bioworks shares in Q3 2024, an estimated $715K.
  • Nikko Asset Management Americas first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Nikko Asset Management Americas's Ginkgo Bioworks position peaked at $106M in Q3 2023.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Nikko Asset Management Americas's 13F filing for Q3 2024, filed 7 Nov 2024.